Practice Management
The Food and Drug Administration (FDA) has approved oral remibrutinib, a new drug product, as a second-line treatment for chronic spontaneous urticaria (CSU). Remibrutinib has a unique mechanism to block the activity of Bruton’s tyrosine kinase (BTK), stopping a key pathway of the immune response in CSU, according to a manufacturer press release. The condition is thought to be caused by immune dysregulation, and it is believed that once activated, BTK leads to the release …
Read More
A new epinephrine nasal spray has been approved by the Food and Drug Administration (FDA) for the treatment of allergic reactions, including anaphylaxis, in adult and pediatric patients who weight at least 66 pounds, according to an FDA press release. Until now, epinephrine has only been available for patients as an injection or auto-injection device. The agency says the new delivery mechanism addresses an unmet need in that some people who need urgent epinephrine treatment …
Read More